- Formycon AG announced a strategic partnership with ATHOS KG valued at approximately €650 million, marking one of the most significant developments in the German biotech company's history. - The collaboration grants Formycon participation rights in two biosimilar candidates, accelerating time-to-market while reducing clinical and regulatory risk compared to in-house development. - The deal structure includes upfront payments, milestone fees tied to regulatory approvals, and commercial royalties, representing a fundamental shift in Formycon's capital allocation strategy. - Biosimilars command higher margins than generic pharmaceuticals due to sophisticated manufacturing requirements and regulatory complexity, positioning Formycon in an attractive market segment driven by patent expirations and healthcare cost containment.

Mar 13, 2026

返回机构列表

ratiopharm GmbH

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（6）

Open label, four-period, two-sequence, fully replicated, randomized, single dose pivotal study for the assessment of bioequivalence between Furosemide 500 mg tablets (Test) and Lasix 500 mg tablets (Reference) in healthy male volunteers under fasting conditions

Akrinor® versus Ephedrine for treatment of hypotension in the peri-operative phase in inpatient setting: a multicenter, prospective, non-interventional study

Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

Randomised, double-blind, multi-centre, placebo-controlled clinical dose finding study in four parallel groups comparing Diclofenac Gel 1 %, Diclofenac Gel 3 %, Diclofenac Gel 5 % and placebo Gel in patients with traumatic blunt soft tissue injury/contusio

Open label, four-period, two-sequence, fully replicated, randomized, single dose pivotal study for the assessment of bioequivalence between Furosemide 500 mg tablets (Test) and Lasix 500 mg tablets (Reference) in healthy male volunteers under fasting conditions

药物批准

按机构分类的批准

近期批准

资讯

Formycon AG Secures €650M Biosimilar Partnership with ATHOS KG in Landmark Deal